MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. Shares 2011-2026 | ZOM
Annual Shares Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 980 M | 980 M | 980 M | 980 M | 957 M | 364 M | 106 M | 93.4 M | 87.4 M | 1 M | 1 M | 340 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 980 M | 340 K | 461 M |
Quarterly Shares Zomedica Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 980 M | 980 M | 980 M | 980 M | 980 M | 980 M | 980 M | 980 M | 980 M | 980 M | 980 M | 980 M | 980 M | 980 M | 980 M | 980 M | 978 M | 974 M | 890 M | 642 M | 551 M | 215 M | 118 M | 108 M | 108 M | 108 M | 101 M | 97.6 M | 94.5 M | 92.5 M | 90.5 M | 90.2 M | 88.8 M | 87.1 M | 84.4 M | 84 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 980 M | 84 M | 591 M |
Shares of other stocks in the Drug manufacturers industry
| Issuer | Shares | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aurora Cannabis
ACB
|
169 M | $ 3.45 | 0.58 % | $ 86.3 M |  Canada |
 |
Alimera Sciences
ALIM
|
25.6 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
150 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
46.3 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
25.8 M | - | 7.5 % | $ 6.35 M | USA |
 |
Canopy Growth Corporation
CGC
|
108 M | $ 1.02 | - | $ 110 M | Canada |
 |
Agile Therapeutics
AGRX
|
2.16 M | - | 10.11 % | $ 58.2 M | USA |
 |
Cronos Group
CRON
|
350 M | $ 2.54 | 1.6 % | $ 1.33 B | Canada |
 |
Assertio Holdings
ASRT
|
6.4 M | $ 11.77 | 1.99 % | $ 836 M | USA |
 |
DURECT Corporation
DRRX
|
26.3 M | - | - | $ 50.1 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
95.1 M | - | - | $ 2.06 B |  France |
 |
Eagle Pharmaceuticals
EGRX
|
12.9 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
64.5 M | $ 5.04 | 0.6 % | $ 325 M | USA |
 |
Evoke Pharma
EVOK
|
3.34 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
50.8 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
127 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Catalent
CTLT
|
181 M | - | - | $ 11.5 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
14.1 M | $ 3.06 | 0.66 % | $ 43 M | USA |
 |
Jupiter Wellness
JUPW
|
54.4 M | - | - | $ 33.6 M | USA |
 |
Athenex
ATNX
|
6.54 M | - | -23.39 % | $ 1.76 M | USA |
 |
Endo International plc
ENDP
|
235 M | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
36.8 M | $ 34.91 | 2.38 % | $ 1.28 B | USA |
 |
Emergent BioSolutions
EBS
|
51.2 M | $ 8.33 | 3.22 % | $ 426 M | USA |
 |
OrganiGram Holdings
OGI
|
256 M | $ 1.42 | 0.71 % | $ 402 M | Canada |
 |
China Pharma Holdings
CPHI
|
17.5 M | $ 0.62 | 2.94 % | $ 10.8 M |  China |
 |
Sundial Growers
SNDL
|
1.86 M | $ 1.44 | -4.64 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
132 M | $ 2.58 | -2.27 % | $ 340 M | USA |
 |
Pacira BioSciences
PCRX
|
46.2 M | $ 22.69 | -2.45 % | $ 1.05 B | USA |
 |
ProPhase Labs
PRPH
|
15.8 M | - | - | $ 5.07 M | USA |
 |
Lannett Company
LCI
|
40.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
Radius Health
RDUS
|
47.2 M | - | - | $ 1.42 B | USA |
 |
Perrigo Company plc
PRGO
|
138 M | $ 9.72 | 4.4 % | $ 1.35 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
492 K | - | - | $ 193 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
1.24 M | $ 2.4 | -2.24 % | $ 2.98 M | USA |
 |
Relmada Therapeutics
RLMD
|
30.1 M | $ 6.18 | 4.57 % | $ 186 M | USA |
 |
Rockwell Medical
RMTI
|
23.3 M | $ 0.96 | 6.61 % | $ 22.4 M | USA |
 |
PetIQ
PETQ
|
29.1 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
112 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
23.7 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
49.9 M | $ 0.9 | 4.68 % | $ 44.9 M | USA |
 |
Recro Pharma
REPH
|
95.2 M | - | -4.76 % | $ 65.3 M | USA |
 |
TherapeuticsMD
TXMD
|
10.4 M | $ 2.17 | - | $ 22.7 M | USA |
 |
Solid Biosciences
SLDB
|
40.8 M | $ 7.48 | 2.33 % | $ 305 M | USA |
 |
Veru
VERU
|
135 M | $ 2.37 | -0.84 % | $ 320 M | USA |
 |
Tilray
TLRY
|
618 M | $ 6.9 | 0.15 % | $ 4.26 B | Canada |
 |
Viatris
VTRS
|
1.2 B | $ 13.51 | - | $ 16.2 B | USA |
 |
Tricida
TCDA
|
51.3 M | - | - | $ 3.25 M | USA |
 |
cbdMD
YCBD
|
4.31 M | $ 0.72 | 1.41 % | $ 3.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
42.7 M | - | - | $ 55.5 M | USA |